Targeting the

Lynn Biderman

Senior Scientist Drug Discovery

Lynn is a passionate scientist that is driven by the desire to promote human health. She has over 13 years of research experience in cancer biology, both in academic and industry settings.  Lynn completed her Ph.D. at Columbia University where she studied the function of the p53 tumor suppressor regulator proteins: Mdm2 and MdmX. During her postdoctoral fellowship at the Rockefeller University, Lynn worked on a genomics and genetic engineering tool for studying small molecule MOA and drug resistance. As a scientist at Inzen Therapeutics, she was part of the Immuno-Oncology team, focusing on assay development and target identification and validation. Lynn joined Stelexis Therapeutic in June 2020 and she is currently leading drug discovery programs.

Jason Fuller

Jason Fuller, Ph.D., is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2021. Prior to Deerfield, Dr. Fuller was an investor at New Enterprise Associates (NEA), where he co-managed several investments in therapeutics, as well as in tools and diagnostics. Previous to NEA, he served as Head of Corporate Development at Jounce Therapeutics, one of several company formation projects he helped initiate in his role as Principal at Third Rock Ventures before joining Jounce. Dr. Fuller holds a B.S. in Chemical Engineering from Michigan State University, an M.Phil. from Cambridge University, and a Ph.D. in Chemical Engineering from Massachusetts Institute of Technology, where he completed his degree in the lab of Robert Langer.

Mark Shtilerman

Mark Shtilerman, Ph.D., is Senior Counsel on the Legal team at Deerfield and joined the Firm in 2014. Dr. Shtilerman has experience counseling companies in all aspects of intellectual property procurement, enforcement and licensing. He is a technically trained patent attorney registered to practice before the USPTO. Prior to Deerfield, Dr. Shtilerman was an attorney in nationally recognized law firms, and before that, was a patent agent at a biotechnology firm. Dr. Shtilerman holds a Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania, a J.D. from Fordham University, and a B.S. in Physics from St. Petersburg State University in Russia. He completed his post-doctoral training at Harvard Medical School and Brigham & Women’s Hospital.

Jonathan Ramos

Jonathan Ramos is an Operations Executive on the External Operations team at Deerfield and joined the Firm in 2017. Prior to Deerfield, Mr. Ramos worked at LEO Pharma, where he spent six years in various finance roles, most recently as LEO’s US Director of Accounting and Compliance. Before LEO, he was Senior Director of Financial Accounting at Triax Pharmaceuticals for three years and a member of Deloitte’s audit practice for four years. Mr. Ramos holds a B.S. in Business Administration with a concentration in Accounting and a Master’s in Professional Accounting from Seton Hall University. He is a Certified Public Accountant.

Uli Steidl

Dr. Steidl trained at the Harvard Stem Cell Institute and held a junior faculty position at Beth Israel Deaconess Medical Center prior to joining the Albert Einstein College of Medicine, where he is now a tenured Professor of Cell Biology and Medicine (Oncology), Program Leader at the NCI-designated Albert Einstein Cancer Center, and a faculty member of the Gottesman Institute for Stem Cell Research. Dr. Steidl’s work has pioneered mechanistic studies and target identification in pre-cancerous and leukemia stem cells, and has resulted in numerous high-profile publications, patents, preclinical development and testing of novel drugs, and clinical trials. Dr. Steidl’s research is supported by the NIH, NYSTEM, NYSCF, the Leukemia & Lymphoma Society, and several other private foundations. He has served as an advisor to numerous large pharma and small/mid sized biotech companies.

Derrick Rossi

Derrick Rossi received his B.Sc. and M.Sc. degrees from the University of Toronto, Canada in the 1990s, and his Ph.D. from the University of Helsinki, Finland, followed by post-doctoral training at Stanford University. Dr. Rossi is an Associate Professor in the Department of Pediatrics at Harvard Medical School. He is also an investigator in the Program in Cellular and Molecular Medicine at Boston Children’s Hospital. Dr. Rossi has been a principal faculty member of the Harvard Stem Cell Institute since 2008.

Dr. Rossi’s lab at Harvard Medical School focuses on diverse aspects of hematopoietic stem cell biology, including how aging of the stem cell compartment contributes to disease pathogenesis and aging-associated hematopoietic decline. His efforts in the development of cutting-edge technologies and new therapeutic strategies are at the forefront of regenerative medicine and biotechnology. Discoveries made in Dr. Rossi’s lab have led to the formation of several leading biotechnology companies. In 2010, Derrick Rossi founded Moderna Therapeutics, a clinical-stage company focused on developing modified-mRNA therapeutics. In 2015, Dr. Rossi co-founded Intellia Therapeutics, a Cambridge-based company focused on developing CRISPR/Cas9 based therapeutics. In 2016, he co-founded Magenta Therapeutics, which is focused on transforming transplantation medicine. Dr. Rossi is currently serving as the founding CEO of Convelo Therapeutics where he leads a team that is developing regenerative therapies for demyelination diseases of the central nervous system. Time magazine cited Dr. Rossi’s discovery of modified-mRNA reprogramming as one of the top ten medical breakthroughs of 2010. Time also named Dr. Rossi as one of the 100 Most Influential People in the world (Time 100) in 2011.

Amit Verma

Dr. Verma is the Director of Division of Hemato-Oncology and Professor of Medicine and Oncology at the Albert Einstein College of Medicine and Montefiore Medical Center. He also heads the MDS Center of excellence clinic at Montefiore. He earned his medical degree at the All India Institute of Medical Sciences, India and finished his postgraduate internal medicine training at the University of Illinois. In addition to clinical duties, Dr. Verma conducts laboratory research exploring the stem cell alterations, epigenomic changes and signaling abnormalities in the pathogenesis of MDS and AML. He is a scholar of the Leukemia and Lymphoma society and his research is funded by the NIH, Department of Defense, American Cancer Society and various private foundations.

Evripids (Evris) Gavathiotis

Evripidis (Evris) Gavathiotis, Ph.D. is an Associate Professor of Biochemistry and Medicine at Albert Einstein College of Medicine and faculty member of the Albert Einstein Cancer Center and the Gottesman Institute for Stem Cell and Regenerative Medicine Research among other institutes. He is conducting innovative research on mechanisms of protein interactions in cell death and cell survival signaling that cause cancer and other diseases and the discovery and optimization of small molecule modulators with the goal of developing new therapeutics. Dr. Gavathiotis’ research has yielded novel signaling mechanisms and pharmacological strategies illustrated in numerous scientific publications and United States patent applications. He has received prestigious awards including the Sidney Kimmel Scholar Award, the 2014 Young Chemical Biologist Award and the Pershing Square Sohn Prize. Dr. Gavathiotis performed postdoctoral research at Rockefeller University and the Dana-Farber Cancer Institute and was a junior faculty at Harvard Medical School. He received his Ph.D. in Biological Chemistry from the University of Nottingham.

Roman Perez-Soler

Roman Perez-Soler is chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore. He is a professor of Medicine and Molecular Pharmacology at the Albert Einstein College of Medicine. A native of Spain, Dr. Perez-Soler received his medical degree from Universidad Autonoma in Barcelona, where he also completed a residency in Internal Medicine. He completed his fellowship in Medical Oncology at the University of Texas, M.D. Anderson Hospital Cancer Center. Dr. Perez-Soler has received numerous awards for his accomplishments, particularly in lung cancer research, and is considered an international key opinion leader.

Uli Steidl

Dr. Steidl trained at the Harvard Stem Cell Institute and held a junior faculty position at Beth Israel Deaconess Medical Center prior to joining the Albert Einstein College of Medicine, where he is now a tenured Professor of Cell Biology and Medicine (Oncology), Program Leader at the NCI-designated Albert Einstein Cancer Center, and a faculty member of the Gottesman Institute for Stem Cell Research. Dr. Steidl’s work has pioneered mechanistic studies and target identification in pre-cancerous and leukemia stem cells, and has resulted in numerous high-profile publications, patents, preclinical development and testing of novel drugs, and clinical trials. Dr. Steidl’s research is supported by the NIH, NYSTEM, NYSCF, the Leukemia & Lymphoma Society, and several other private foundations. He has served as an advisor to numerous large pharma and small/mid sized biotech companies.

Derrick Rossi

Derrick Rossi received his B.Sc. and M.Sc. degrees from the University of Toronto, Canada in the 1990s, and his Ph.D. from the University of Helsinki, Finland, followed by post-doctoral training at Stanford University. Dr. Rossi is an Associate Professor in the Department of Pediatrics at Harvard Medical School. He is also an investigator in the Program in Cellular and Molecular Medicine at Boston Children’s Hospital. Dr. Rossi has been a principal faculty member of the Harvard Stem Cell Institute since 2008.

Dr. Rossi’s lab at Harvard Medical School focuses on diverse aspects of hematopoietic stem cell biology, including how aging of the stem cell compartment contributes to disease pathogenesis and aging-associated hematopoietic decline. His efforts in the development of cutting-edge technologies and new therapeutic strategies are at the forefront of regenerative medicine and biotechnology. Discoveries made in Dr. Rossi’s lab have led to the formation of several leading biotechnology companies. In 2010, Derrick Rossi founded Moderna Therapeutics, a clinical-stage company focused on developing modified-mRNA therapeutics. In 2015, Dr. Rossi co-founded Intellia Therapeutics, a Cambridge-based company focused on developing CRISPR/Cas9 based therapeutics. In 2016, he co-founded Magenta Therapeutics, which is focused on transforming transplantation medicine. Dr. Rossi is currently serving as the founding CEO of Convelo Therapeutics where he leads a team that is developing regenerative therapies for demyelination diseases of the central nervous system. Time magazine cited Dr. Rossi’s discovery of modified-mRNA reprogramming as one of the top ten medical breakthroughs of 2010. Time also named Dr. Rossi as one of the 100 Most Influential People in the world (Time 100) in 2011.